<DOC>
	<DOCNO>NCT00612183</DOCNO>
	<brief_summary>The purpose study assess antitumor effect safety bendamustine hydrochloride ( SyB L-0501 ) patient indolent B-cell non-Hodgkin 's lymphoma mantle cell lymphoma .</brief_summary>
	<brief_title>Clinical Study SyB L-0501 Patients With Indolent B-cell Non-Hodgkin 's Lymphoma Mantle Cell Lymphoma</brief_title>
	<detailed_description>Indolent B-cell Non-hodgkin 's lymphoma treat mainly radiation chemotherapy use combination chemotherapy , purine-analogues CHOP ( cyclophosphamide , doxorubicin , vincristine prednisolone ) . After approval antibody therapy agent RituximabÂ® , alone combination CHOP introduce . Bendamustine hydrochloride unique structure compare marketed agent , innovative mechanism action . Thus , expect Bendamustine hydrochloride provide new alternative patient refractory/recurrent indolent B-cell Non-hodgkin 's lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>NonHodgkin 's lymphoma patient prior therapy satisfy condition list . No restriction regard gender . Patients histologically cytologically confirm indolent B cell NonHodgkin 's lymphoma mantle cell lymphoma . Patients receive treatment least 4 week ( least 12 week case antibody therapy ) completion prior therapy judge carry effect prior therapy . Patients age 20 less 75 year . Performance Status ( P.S . ) : 0 1 . Patients adequately maintain organ function ( e.g. , bone marrow , heart , lung , liver , kidney function ) . Patients write consent participate study obtain . Patients meet follow criterion exclude . Patients apparent infection . Patients serious complication ( hepatic failure renal failure ) . Patients complication history serious heart failure ( e.g . cardiac infarction , ischemic heart disease ) . Patients serious digestive symptom ( nausea/ vomiting/ diarrhea ) . Patients know positive HBV , HCV HIC . Patients receive investigational drug within 3 month registration study . Patients allogenic bonemarrow transplant . Women pregnant , childbearing potential , lactate . Patients agree contraception . Otherwise , patient judge investigator unsuitable inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
</DOC>